Loading
Progyny, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Anevski Peter, was filed 17 Nov 2025.
Progyny, Inc.: what insiders have been doing
Every trade that managers of Progyny, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in United States. 15 insiders have disclosed 50 filings since 18 October 2025.
Open-market activity splits into 1 purchase totalling €1.7M and 5 sales totalling €1.2M; 1 insider sit on the buying side and 3 insiders on the selling side. Netting one side against the other leaves €438k of net buying. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Among those who bought: 1 chief executive. Biggest ticket of the year: €1.7M, bought by Anevski Peter and made public on 17 November 2025.
The last purchase on record was published on 17 November 2025, which is 335 days ago. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Across the 5,813 companies tracked on its exchange, the median is 19 filings; at 50 filings, this issuer sits above that mark. Looking back to 2021, when coverage begins, insiders filed 3 purchases and 103 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 1.29 bn USD and net income at 58.5 m USD.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
430
Thresholds
n/a
Buy Volume
€7M
3 ops. · all time
Sell Volume
€256M
103 ops. · all time
Who traded when
BuySaleKevin K. Gordon3 sales
Melissa B. Cummings3 sales
Mark S. Livingston2 sales
Peter Anevski2 buys
Swartz Allison2 sales
Schlanger David J1 buy
+1 other insider
Since the insiders bought
- -21.3%Entry US$25.85 · Close at T+90 US$20.35
- +51.6%Entry US$16.90 · Close at T+365 US$25.62
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Progyny, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$34.42.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 10,011 of 23,476 companies
55.4
score / 100
Value49
Quality62
FCF yld9.3%
Earn yld2.8%
EV/EBITDA23.1x
ROE16%
Gross mgn24%
Net mgn4.5%
Debt/EBITDA0.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$27.84
Analyst consensus
12 analystsStrong buy
US$30.00Target US$34.42(+24%)US$40.00
Income statement
RevenueUS$1.3B
Gross profitUS$304.5M24% margin
EBITDAUS$90.2M7% margin
Net incomeUS$58.5M6.0% margin
Valuation
PER (trailing)30.3x
PER (forward)12.0x
P/Book4.7x
Beta1.02
Balance sheet & cash
Market capUS$2.1B
Total debtUS$27.7M
Free Cash FlowUS$191.8M
Debt / Equity6%
Profitability & ownership
ROE16.2%
ROA10.1%
% insiders2.0%
% institutions110.3%
Last declaration on 16 October 2026
Declarations430 total
1,559 shares@ US$27.390.0020% mcap7.7% of flowCommon StockSEC:0001551306-26-000160:0
1,879 shares@ US$28.000.0025% mcap11.5% of flowCommonSEC144:0001959173-26-007367
3,903 shares@ US$26.100.0051% mcap14.2% of flowCommonSEC144:0001959173-26-007087
819 shares@ US$27.380.0011% mcap19.0% of flowCommon StockSEC:0001551306-26-000156:0
11,500 shares@ US$27.11810.015% mcap18.7% of flowCommon StockSEC:0001551306-26-000154:2
22,000 shares@ US$13.000.014% mcap17.1% of flowCommon StockSEC:0001551306-26-000152:0
10,500 shares@ US$27.240.014% mcap17.1% of flowCommon StockSEC:0001551306-26-000152:1
11,500 shares@ US$27.94420.016% mcap19.3% of flowCommon StockSEC:0001551306-26-000152:2
11,500 shares@ US$27.11810.015% mcap18.7% of flowCommonSEC144:0001959173-26-006853
479 shares@ US$26.610.0006% mcap0.4% of flowCommon StockSEC:0001551306-26-000146:0
5,361 shares@ US$26.290.0070% mcap0.5% of flowCommon StockSEC:0001551306-26-000150:0
828 shares@ US$26.290.0011% mcap3.0% of flowCommon StockSEC:0001551306-26-000148:0
479 shares@ US$26.610.0006% mcap1.7% of flowCommon StockSEC:0001551306-26-000148:1
224 shares@ US$25.660.0003% mcap0.2% of flowCommon StockSEC:0001551306-26-000144:0
1,532 shares@ US$26.290.0020% mcap1.3% of flowCommon StockSEC:0001551306-26-000144:1
1,193 shares@ US$31.980.0019% mcap9.3% of flowCommon StockSEC:0001551306-26-000131:0
2,244 shares@ US$31.600.0036% mcap17.2% of flowCommonSEC144:0001959173-26-005215
819 sharesCommon StockSEC:0001551306-26-000129:0
5,361 shares@ US$25.120.0054% mcap0.5% of flowCommon StockSEC:0001551306-26-000124:0
599 shares@ US$25.080.0006% mcap2.1% of flowCommonSEC144:0001959173-26-004332
2,517 shares@ US$25.500.0025% mcap2.0% of flowCommonSEC144:0001959173-26-004340
1,199 shares@ US$25.020.0012% mcap4.1% of flowCommonSEC144:0001959173-26-004285
1,530 shares@ US$25.580.0015% mcap32.7% of flowCommonSEC144:0001959173-26-004260
279 shares@ US$26.200.0003% mcap0.2% of flowCommonSEC144:0001959173-26-004250
5,660 shares0Common StockSEC:0001551306-26-000107:0
25 of 430 declarations
About Progyny, Inc.
Progyny, Inc. (ticker: PGNY) is listed on the U.S. Nasdaq market in the United States. For investors, it is a healthcare benefits company focused on fertility, family-building, and women’s health. The business is not a traditional insurer; instead, Progyny designs benefit solutions and clinical navigation services for employers, health plans, and other benefit purchasers. Its platform combines a curated provider network, care coordination, integrated pharmacy services, and personalized member support, positioning the company as a specialist in a niche but strategically important segment of employee health benefits. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1551306/000155130625000040/pgny-20241231.htm?utm_source=openai))
Progyny was originally incorporated in 2008, changed its name to Progyny, Inc. in 2015, and is headquartered in New York, New York. Its corporate development has been tied to the growth of fertility benefits in the U.S., a category that historically received limited coverage from employers and health plans. Over time, Progyny built a reputation as one of the leading independent specialists in this market, with an emphasis on clinical outcomes, member experience, and streamlined access to reproductive specialists and related services. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001551306/000155130626000020/pgny-20251231.htm?utm_source=openai))
Read moreShow less
Operationally, the company’s core revenue base centers on fertility benefit services and Progyny Rx, its integrated pharmacy solution. In recent periods, Progyny has also expanded its offering into adjacent areas including maternal health, doula services, men’s health support, and broader women’s health solutions such as menopause and midlife care. This broader product set supports a strategy of becoming a more comprehensive women’s health and family-building platform while remaining anchored in its original fertility-benefits niche. ([investors.progyny.com](https://investors.progyny.com/news-releases/news-release-details/progyny-inc-announces-fourth-quarter-2025-results?utm_source=openai))
From a competitive standpoint, Progyny’s main advantage is specialization. Compared with large diversified insurers and broad employee-benefits platforms, the company differentiates itself through a focused clinical model, a managed provider ecosystem, and proprietary benefit design centered on better care navigation. The company also highlights strong member satisfaction and favorable clinical metrics, which help support its premium positioning with large employers that view reproductive-health benefits as both a talent-retention tool and a strategic HR offering. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1551306/000155130625000040/pgny-20241231.htm?utm_source=openai))
Recent developments have been notable. In 2025, Progyny reported continued revenue growth, while also disclosing that one large client did not renew and that the transition period extended into the first half of the year. By early 2026, the company reported another strong year and launched Progyny Select, described as the industry’s first fully insured supplemental fertility and family-building plan for small U.S. employers. For equity investors, PGNY remains a growth-oriented healthcare services name on Nasdaq, with exposure to U.S. employment trends, employer benefit spending, and ongoing demand for reproductive and women’s health solutions. ([investors.progyny.com](https://investors.progyny.com/news-releases/news-release-details/progyny-inc-announces-fourth-quarter-2025-results?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
